Overview

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Status:
Active, not recruiting

Trial end date:
2023-03-15

Target enrollment:

Participant gender:

Summary

This is a multicenter, 2-cohort Phase 2 study assessing both MRD-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or SLL

Phase:

Phase 2

Details

Lead Sponsor:

Pharmacyclics LLC.

Collaborators:

Janssen Research & Development, LLC
Janssen Research and Development LLC

Treatments:

Venetoclax